Ernst has over 15 years of experience in cancer research, oncology drug development and venturing. He has been working on both sides of the table as an executive in new venture creation and as an investor in oncology start-ups. He developed this entrepreneurial spirit in his academic life working in the laboratory of Hidde Ploegh at Harvard Medical School and at the translational cancer research group of Prof. Rene Bernard at the Netherlands Cancer Institute. He continued his career as business developer at the research- and technology organization TNO, where he had a role in spinning-out biotech companies.
Ernst supports Aglaia in the analysis of investment proposals and offers strategic support on an ad hoc basis to Aglaia’s portfolio companies. He was interim managing director of Sapreme Technologies and was part of business and R&D strategy task forces for Mimetas, Inthera Bioscience and Macrophage Pharma.